Osteoporosis is a disease characterized by low bone mass and deterioration of bone structure. It increases bone fragility and risk of fractures. Primary types include postmenopausal osteoporosis in women over 50 and senile osteoporosis in those over 70. Treatment focuses on preventing bone loss and increasing bone mass. First line drugs are bisphosphonates like alendronate and risedronate. Second line includes selective estrogen receptor modulators like raloxifene. Non-pharmacological prevention focuses on calcium, vitamin D, and weight-bearing exercise.
2. OSTEOPOROSIS
2
World Health Organization
“A bone mineral density < 2.5 standard deviation below the
young normal mean.”
A systematic skeletal disease characterized by low bone
mass and micro architectural deterioration of bone tissue.
Consequent increase in bone fragility and susceptibility to
fractures with minimal trauma
3. TYPES OF OSTEOPOROSIS
3
PRIMARY
Type I (postmenopausal osteoporosis)
Women > men, typically develops between 50 and 70yrs.
Results in decrease in the amount of trabecular bone
(the spongy bone inside of hard cortical bone).
Type II osteoporosis (senile osteoporosis)
Typically happens after 70yrs and affects women twice as
frequently as men.
Thinning of both trabecular bone and hard cortical bone.
4. SECONDARY
Due to systemic illness or medication (glucocorticoid)
Most successful approach: prompt resolution of
underlying cause or drug discontinuation
4
5. RISKS FOR OSTEOPOROSIS
5
In young women
Low calcium intake
Low body weight
Hypoestrogenism
In others
Menopausal/postmenopausal
status without HRT
Cigarette smoking
Alcohol consumption
Low-trauma fractures
Hyperparathyroidism
Chronic corticosteroid use
7. DIAGNOSIS
7
A medical evaluation to diagnose osteoporosis and
estimate risk of breaking a bone may involve one or
more of the following steps:
Medical history
Physical examination
Bone density test
Laboratory tests
8. DENSITOMETRIC EVALUATION BY
DUAL ENERGY X RAY
Only test that can diagnose osteoporosis before a broken
bone occurs.
Helps to estimate the density of bones and chance of
breaking a bone.
At present, DEXA scanning focuses on two main areas hip
and spine.
8
9. LABORATORY TESTS
9
Blood calcium levels
24-hour urine calcium measurement
Parathyroid hormone levels
Testosterone levels in men
25-hydroxyvitamin D test to determine whether the body
has enough vitamin D.
12. NON-PHARMACOLOGICAL
TREATMENT
Nutrition:
Calcium supplementation as needed
most common: Calcium Carbonate (1200 mg total)
Vitamin D as needed (400 IU to 800 IU daily)
Exercise: weight bearing and strength training exercises.
Multiple health benefits
Fall prevention and/or hip protectors in the frail elderly
Avoiding alcohol and tobacco abuse ( osteoblastic activity).
12
13. TREATMENT OF OSTEOPOROSIS
13
Bone loss in osteoporosis results from an imbalance
between the two components of the bone renewal
process: Bone Resorption And Bone Formation.
The goal of treatment is to prevent bone fractures by:
Stopping bone loss (Antiresorptive)
Increasing bone mass and strength (Anabolic)
17. CELLULAR MECHANISM OF ACTION
1. Osteoclast actively reabsorbs bone matrix
2. Bisphosphonate ( ) binds to bone
mineral surface
3. Bisphosphonate is taken up by
the osteoclast
4. Osteoclast is inactivated
5. Osteoclast becomes apoptotic and dies
17
18. PRECAUTIONS
18
Administered with a full glass of water following an
overnight fast and at least 30 minutes before breakfast
and should remain upright
Patients with active upper GI disease, decreased renal
function should not be given oral bisphosphonates
20. ALENDRONATE
20
II generation nitrogen containing bisphosphonate.
for prevention and
treatment of steroid
FDA approved on 7 April 2005
treatment of postmenopausal and
induced osteoporosis.
Decreases risk of vertebral & hip fractures.
21. 5-10 mg daily dose/ 30-35mg weekly, orally.
Taken on empty stomach with glass of water, should not
lie down for half hour.
Maximum duration of therapy is for 7 yrs.
Side effects - esophagitis, myalgias.
21
22. PAMIDRONATE
22
II generation bisphosphonate.
Available only as IV preparation because of poor GI
absorption and high frequency of GI symptoms.
I.V. Pamidronate: approved for Hypercalcemia of
malignancy & other skeletal disorders, Paget’s disease.
Adverse effects: bone pain, thrombophelebitis of vein, fever,
leucopenia.
Acute and delayed hypersensitivity reaction can occur with
i.v pamidronate.
23. IBANDRONATE
23
II generation bisphosphonate
Administered every 3 months as single intravenous injection
over a period of 15 to 30 seconds.
Approved for prevention and treatment of Osteoporosis
related vertebral fracture in 6 January 2006.
Compliance with monthly dose is good.
24. ZOLENDRONATE
24
III generation bisphosphonate
Approved: treatment of malignant hypercalcemia, multiple
myeloma and skeletal metastasis on 20 August 2001.
Inhibition of proliferation of bony metastasis of prostate /
breast cancer.
Only available in IV preparation. 4mg/day for one year.
Dose Reduction in bone turnover and increased bone mineral
density.
Osteonecrosis of jaw is adverse effect with long term use.
25. RISEDRONATE
25
Third generation nitrogen containing bisphosphonate.
FDA approved in 27 march 1998 for prevention and
treatment of postmenopausal and steroid induced
osteoporosis.
Reduced incident of vertebral and hip fracture.
Dose is 5 mg daily or 30-35 mg weekly, orally
S/E esophagitis, myalgias, less compliance
26. BISPHOSPHONATE SIDE EFFECTS
GIT upset: Inflammation/erosions of esophagus.
Nausea, dyspepsia.
Fever/flu-like symptoms- myalgias, arthalgias.
Increased risk of Atrial fibrillation.
Transient hypocalcaemia with secondary hyperparathyroidism.
Ocular inflammation.
Bisphosphonate related ostionecrosis of jaw. 27
28. SERMs are ER ligands that act like estrogens (agonist) in
bone, liver & estrogen antagonist in breast tissue.
Classification:
Tamoxifen and analogues:
Tamoxifen, Toremifene, Droloxifene, Idoxifene
Fixed ring compound
Raloxifene, Lasofoxifene, Arzoxifen, Miproxifene,
Ormeloxifene, Levormeloxifene.
28
29. The “Ideal” SERM Would be
Strengthen bones
Lower LDL cholesterol and raise HDL cholesterol
Relieve hot flushes
Reduce breast cancer risk
Reduce uterine cancer risk
29
30. RALOXIFENE
30
It non-specifically acts on both the estrogen receptors ERα
and ERβ.
It act as partial agonist in bone & cardiovascular system,
antagonist endometrium & breast.
It prevent bone loss, increases bone mineral density, agonist
activity in lipid metabolism and coagulation profile.
Increases Bone Mineral Density (BMD) by 0.9-3.4 % and
reduces the risk of vertebral fractures.
Less effective than bisphosphonate.
31. Pharmacokinetics:
Well absorbed orally
Dose 60 mg once a day
Use:
Prevention and treatment of postmenopausal osteoporosis
in women.
Prevention of breast cancer in women having risk factor.
Adverse Effect:
Hot flushes, leg cramps, vaginal bleeding.
Increased risk of venous thromboembolism
31
32. CALCITONIN
32
Inhibits bone resorption by action on osteoclast by reducing
contact of osteoclast with respective pit.
Reduces the remodeling space.
Significantly reduces vertebral fracture than non-vertebral
fracture in postmenopausal women.
Calcitonin: 200 units daily by nasal spray
Approved for treatment (not prevention)
Adverse effects: nausea, flushing, epistaxis, nasal
stuffiness.
33. VIT-D
33
Increases recruitment & differentiation of osteoclast
precursor.
Reduces bone remodeling.
Acts on osteoblast cell to increase bone mineralization
indirectly by maintaining plasma calcium concentration.
Osteoporosis due to hyperparathyroididsm
Dose: 100-200,000 IU of vitamin D2 or D3, orally daily or
every two months for six months.
34. TERIPARATIDE
34
It is recombinant human parathyroid hormone analogue.
FDA has approved in 2002 for severe osteoporosis.
Only agent that increases new bone formation (Anabolic)
Increases the axial bone mineralization but has no effect
on cortical bone.
Also for treatment of osteoporosis in men and women who
are at high risk of breaking a bone as a result of taking
steroid medicines for a long time.
35. Significantly increases bone mineral density, especially in
the spine.
Faster acting than bisphosphonate & SERMs
Effective in glucocorticoid induced osteoporosis.
Dose is 20 μ
gper day SC.
Side effects: leg cramps and dizziness.
35
37. NERIDRONATE
37
It’s an amino bisphosphonate, licensed in Italy for the
treatment of osteogenesis imperfecta (OI) and Paget’s
disease of bone (PDB).
Completed phase 3 .
Neridronate may be administered both intravenously and
intramuscularly.
More potent than first generation bisphosphonate.
38. DENOSUMAB
38
FDA approved for osteoporosis in 2011.
It’s a monoclonal antibody
Binds to RANKL, a protein involved in the formation,
function, and survival of osteoclasts, the cells responsible
for bone resorption.
Denosumab resulted in a statistically significant effect on
BMD as compared to placebo in patients with non
metastatic prostate or breast cancer.
39. Significantly reduced the incidence of new vertebral
fractures.
Dose: 120 mg subcutaneously every 4 weeks.
S/E: arthralgia and back pain due to hypocalcaemia.
39
40. ROMOSOZUMAB
40
Humanized monoclonal antibody that targets sclerostin for
the treatment of osteoporosis.
Sclerostin is expressed in osteocytes and some
chondrocytes and it inhibits bone formation by osteoblasts.
Phase 3 of clinical trial.
Increased bone density in the hip and spine in healthy men
and postmenopausal women.
41. CATHEPSIN K INHIBITORS
41
Cathepsin K is a protease which has high specificity
for kinins, that is involved in bone resorption.
The enzyme's ability to catabolize elastin, collagen,
and gelatin allows it to break down bone and cartilage.
Inhibition of Cathepsin K enzyme decreases the bone
resorption.
42. ODANACATIB
42
Phase 3 of clinical trial.
It significantly reduced the risk of osteoporotic fractures
compared to placebo .
Once weekly 50 mg injection is given.
Adverse Effect: atrial fibrillation, skin rashes, stroke,
cereberovascular event.
43. SRC KINASE INHIBITORS
43
SARACATINIB
Src is a non receptor tyrosine kinase thought to be essential
for osteoclast function and bone resorption.
Inhibits bone resorption by inhibiting osteoclast function.
Phase 2 of clinical trial.
S/E: anemia, nausea, anorexia, asthenia, pyrexia, vomiting,
diarrhea
44. TEDUGLUTIDE
44
Glucagon-like peptide 2 (GLP-2) analog.
Most bone loss takes place at night and may be linked to
food intake.
Bone resorption marker fall after feeding & GLP-2 level
rises after feeding.
GLP-2 at bedtime significantly reduces overnight bone loss.
Phase 2 of clinical trial for osteoporosis.
45. ABALOPARATIDE
45
It’s a new synthetic peptide analog of hPTHrP (human
parathyroid hormone-related protein).
Phase 2 clinical trials.
Reduction of fractures in postmenopausal osteoporosis.
Statistically significant increases in BMD at the lumbar
spine, total hip, and femoral neck.
46. LASOFOXIFENE
46
Phase 3 of clinical trial.
Third generation SERM.
Good oral bioavailability
Proapoptotic effect on osteoclast precursors.
Adverse Effect: hot flashes, leg cramps, 2-fold increased
risk of venous thromboembolism
47. BAZEDOXIFENE
47
Phase 3 of clinical trial postmenopausal osteoporosis.
Approved in the European Union (marketed in Italy, Spain).
Significant decrease in metabolic bone markers was seen
with bazedoxifene treatment compared to placebo.
Decreases the vertebral fracture than non-vertebral.
S/E: hot flushes, leg cramps
49. CONCLUSION
49
Osteoporosis is a significant health risk – particularly in
postmenopausal women and men over 65.
First line drugs for treatment of osteoporosis
are bisphosphonates, second line drug are
SERM.
Eat a well-balanced diet rich in calcium and vitamin D.
Engage in regular physical activity or exercise.
Weight-bearing activities, such as walking, jogging,
dancing, and lifting weights, are the best for strong bones.
50. REFERENCES
50
Goodman and Gilman’s, Agents affecting Mineral ion homeostasis
and bone turnover, chapter 44, the pharmacological basis of
therapeutics, 12th edition,1275
Bertram G. Katzung, Agents affecting Mineral ion homeostasis
and bone turnover, chapter 42, Basic and Clinical Pharmacology,
13th edition, 1008
H. Sharma, estrogens, drugs affecting calcium balance, chapter
43,46; principles of pharmacology, 3rd edition, 584,624
https://www.fda.gov/downloads/drugs/newsevents/ucm470574.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426100